{"id":6783,"date":"2026-03-23T15:38:34","date_gmt":"2026-03-23T14:38:34","guid":{"rendered":"https:\/\/hemerapharma.com\/?p=6783"},"modified":"2026-03-24T16:07:15","modified_gmt":"2026-03-24T15:07:15","slug":"osservatorio-terapie-avanzate-features-remast","status":"publish","type":"post","link":"https:\/\/hemerapharma.com\/en\/osservatorio-terapie-avanzate-features-remast\/","title":{"rendered":"Osservatorio Terapie Avanzate features Hemera and the regenerative medicine challenge behind REMaST\u00ae"},"content":{"rendered":"

Hemera is featured in an article published by Osservatorio Terapie Avanzate<\/span><\/span><\/a>, a leading Italian editorial platform focused on scientific information<\/strong> and analysis of innovations in advanced therapies, regenerative medicine, and biotechnology.<\/strong><\/p>\n

In the interview, Cristiana Vignoli<\/span><\/span><\/a>, CEO of Hemera, and Ilaria Decimo<\/span><\/span><\/a>, Co-founder and Head of Research & Development, discuss the scientific and industrial pathway behind the REMaST\u00ae<\/a>, a regenerative cell therapy technology currently in development for the treatment of spinal cord injuries<\/strong>.<\/p>\n

The article explores the scientific foundation of the therapeutic platform, based on reprogrammed macrophage to activate regenerative processes in damaged nervous tissue,<\/strong> together with preclinical results<\/a> demonstrating the ability to promote nerve fiber regrowth and functional recovery in experimental models.<\/p>\n

A key highlight is the recent publication in Immunity<\/span><\/span><\/em><\/a>, a international scientific journal by Cell Press<\/span><\/span><\/em>, which featured the Hemera study on its cover. The research demonstrates how specific macrophage populations express a genetic signature associated with neuronal growth, contributing to synapse formation and axonal regeneration.<\/strong><\/p>\n

This evidence further strengthens the scientific rationale of the REMaST platform and opens new perspectives in addressing one of the longstanding challenges in medicine:<\/strong> the limited regenerative capacity of the central nervous system.<\/p>\n

\n

As highlighted by Ilaria Decimo<\/span><\/span>:
\u201cUsing macrophages means acting on the lesion microenvironment, activating multiple biological processes in a coordinated way to support nerve tissue regeneration.\u201d<\/p>\n<\/blockquote>\n

The interview also addresses key challenges related to the translational phase<\/strong>, including regulatory pathways, industrial development, and manufacturing scalability, critical elements for advancing from preclinical validation to clinical application.<\/p>\n

In this context, REMaST is currently in an advanced development stage<\/strong>, with the objective of initiating the first-in-human clinical study<\/em> and progressing toward a cure for patients.<\/p>\n

\n

As noted by Cristiana Vignoli<\/span><\/span>:
\u201cTransforming research results into concrete therapeutic solutions is the central challenge in delivering real innovation to patients.\u201d<\/p>\n<\/blockquote>\n

\ud83d\udc49 Read the full interview here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Hemera is featured in an article published by Osservatorio Terapie Avanzate, a leading Italian editorial platform focused on scientific information and analysis of innovations in advanced therapies, regenerative medicine, and biotechnology. In the interview, Cristiana Vignoli, CEO of Hemera, and Ilaria Decimo, Co-founder and Head of Research & Development, discuss the scientific and industrial pathway […]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[31,34],"tags":[],"class_list":["post-6783","post","type-post","status-publish","format-standard","hentry","category-news-en","category-press-review"],"acf":[],"_links":{"self":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/comments?post=6783"}],"version-history":[{"count":1,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6783\/revisions"}],"predecessor-version":[{"id":6784,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6783\/revisions\/6784"}],"wp:attachment":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/media?parent=6783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/categories?post=6783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/tags?post=6783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}